Company Profile
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (brand: Mindray) is a China-based manufacturer of patient monitoring, in-vitro diagnostics (IVD), and medical imaging systems, headquartered in Nanshan District, Shenzhen, Guangdong. Founded in 1999 and listed on the Shenzhen Stock Exchange (300760) in 2018, the company is led by Chairman Li Xiting and Managing Director Wu Hao. Mindray serves over 200,000 medical institutions in more than 190 countries and regions.
Core Products ＆ Technologies
Patient Monitoring ＆ Life Support
• Patient Monitoring Systems: Multi-parameter patient monitors, central monitoring stations, and telemetry systems for ICU, OR, and general wards
• Anesthesia Machines: Advanced anesthesia workstations with integrated ventilation and gas monitoring
• Ventilators: Mechanical ventilators for adult, pediatric, and neonatal critical care
• Defibrillators ＆ AED: Automated external defibrillators (AED) and professional defibrillation systems; Mindray AEDs have successfully resuscitated 451 public cardiac arrest patients in China as of March 2026
• Infusion ＆ Syringe Pumps: Smart infusion systems with drug library and dose error reduction
In-Vitro Diagnostics (IVD)
• Chemiluminescence Immunoassay (CLIA): Fully automated CLIA analyzers with expanding menu of tumor markers, thyroid, infectious disease, cardiac markers, and autoimmune antibodies; 95 NMPA-registered and 101 CE-registered chemiluminescence reagents as of March 2026
• Hematology Analyzers: 5-part differential blood cell counters and coagulation systems
• Clinical Chemistry: Automated biochemistry analyzers for routine and specialized testing
• Molecular Diagnostics: Nucleic acid testing platforms and reagents
• Coagulation Testing: Coagulation factor assays including FⅧ, FⅨ, Anti-Xa, and vWF antigen testing; CX-9600 fully automated coagulation analyzer launched in Q1 2026
Medical Imaging
• Ultrasound Systems: Premium, mid-range, and portable ultrasound platforms including the EagusI9 intraoperative visualization system and MU9/7 portable color Doppler series launched in Q1 2026
• Digital Radiography (DR): Fixed and mobile X-ray systems
• Computed Tomography (CT): CT scanners for diagnostic imaging
Emerging Businesses
• Minimally Invasive Surgery: High-value consumables including ultrasonic scalpels and laparoscopic staplers; disposable electronic ureterorenoscopy imaging catheter launched Q1 2026
• Minimally Invasive Intervention: Expansion catheters, coronary balloon catheters, and transjugular intrahepatic access devices via subsidiary Huitai Medical (惠泰医疗)
• Animal Health: Veterinary diagnostic and monitoring equipment achieving double-digit growth
• Oral Care ＆ Others: Additional healthcare product lines
Market Position ＆ Certifications
Mindray holds a leading position in China's domestic medical device market and is a top-50 global medical device company, competing with Philips Healthcare, GE Healthcare, Siemens Healthineers, Medtronic, and Abbott. Key strengths include:
• 26+ years of medical device innovation heritage
• Global scale: International revenue reached RMB 4.449 billion in Q1 2026 (up 15.70% YoY), accounting for 53% of total revenue; European market grew over 25%
• High R＆D intensity: Q1 2026 R＆D investment of RMB 889 million, representing 10.64% of revenue; cumulative patent applications of 13,159 (including 9,533 invention patents) with 6,713 granted patents (including 3,512 invention patents) as of March 2026
• Regulatory compliance: NMPA Class II and III registrations, CE marked products, and FDA cleared devices
• Shareholder returns: Eight consecutive years of dividends since 2018 A-share listing; cumulative dividends of approximately RMB 373.36 billion by end of 2025, projected to reach RMB 392.27 billion after 2025 annual and 2026 first interim dividends
Corporate Timeline
1999 — Founded in Shenzhen as a foreign-invested enterprise with USD 2 million registered capital
2006 — Listed on New York Stock Exchange (subsequently privatized in 2016)
2018 — Listed on Shenzhen Stock Exchange (300760), raising RMB 5.934 billion in IPO
2021 — Acquired controlling stake in Huitai Medical (惠泰医疗), expanding into minimally invasive interventional cardiology
2024 — Annual revenue reached RMB 36.726 billion
2025 — Annual revenue of RMB 33.282 billion; continued global expansion with overseas revenue exceeding 50% of total in Q4; launched MAGLUMI X10 and other high-end platforms
2026 — Q1 revenue of RMB 8.352 billion (up 1.39% YoY) with international revenue at 53% of total; emerging business grew 18.22% to RMB 1.398 billion; proposed 2025 annual dividend of RMB 3.10 per 10 shares and 2026 first interim dividend of RMB 12.50 per 10 shares
Target Markets ＆ Applications
• Critical Care ＆ Emergency Medicine: Patient monitoring, ventilators, anesthesia, and defibrillation for ICUs, ORs, and emergency departments
• Clinical Laboratory Diagnostics: Chemiluminescence, hematology, biochemistry, and coagulation systems for hospital labs and reference centers
• Diagnostic Imaging: Ultrasound, DR, and CT for radiology, cardiology, and point-of-care settings
• Minimally Invasive Surgery: Surgical energy devices and endoscopic consumables for laparoscopic and urological procedures
• Interventional Cardiology: Catheters, balloons, and access devices via Huitai Medical subsidiary
• Veterinary Medicine: Diagnostic and monitoring equipment for companion and livestock animal health
• Global Healthcare Systems: Products serving from primary care clinics to tertiary hospitals across developed and emerging markets
Contact Information
Global Headquarters
Address: Mindray Building, No. 12 Keji South Road, Nanshan District, Shenzhen, Guangdong 518057, China
Phone: +86 755 8188 8898
Fax: +86 755 2658 2699
Email: IR@mindray.com
Website: www.mindray.com
